Jackson Gao, MD
Hematology & Oncology · York, PANPI 1538663208
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by AstraZeneca at 42.4% of the total.
Across 58 payments — averaging $463.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$11K
- Gilead$7K
- Johnson & Johnson$3K
- Beone Medicines USA, Inc.$2K
- Beigene USA, Inc.$2K
- Avyxa Pharma, LLC$1K
- plus $637 from 7 others
Across 3 payments — averaging $33,682 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$101K
What the payments were for
- Consulting fees$15,11056%
- Speaking & faculty fees$9,59036%
- Travel & lodging$5072%
- Food & beverage$1,5866%
- Education$1070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 11 | $11,416 |
| Gilead | 12 | $6,719 |
| Johnson & Johnson | 3 | $2,845 |
| Beone Medicines USA, Inc. | 6 | $2,002 |
| Beigene USA, Inc. | 3 | $1,970 |
| Avyxa Pharma, LLC | 2 | $1,310 |
| AbbVie | 7 | $158 |
| Genentech USA, Inc. | 5 | $135 |
| Astellas Pharma US Inc | 4 | $113 |
| Tempus AI, Inc | 1 | $107 |
| Accord Healthcare, Inc. | 1 | $89 |
| Iovance Biotherapeutics, Inc. | 2 | $21 |
| Agios Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,900 in reported general payments places this provider in the 85th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $10,434 |
| Letrozole | 43 | $815 |
| Oxycodone Hcl | 16 | $412 |
| Hydroxyurea | 14 | $301 |
| Prochlorperazine Maleate | 33 | $292 |
| Dexamethasone | 32 | $235 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in York
- Daniel Efiom-EkahaYork$346K
- Chanh HuynhYork$115K
- Dan SotirescuYork$114K
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.